Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial
KU Leuven · University of Calgary · +27 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
308
total citations
- FWCI
- 52.19
- Percentile
- 100%
- References
- 21
Citations per year
Authors
31Topics & keywords
Topics
Keywords
- Medicine
- Placebo
- Maintenance therapy
- Crohn's disease
- Internal medicine
- Clinical trial
- Physical therapy
- Disease
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.